Testing IAP0971 in advanced solid tumors and lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called IAP0971 for people with advanced solid tumors or a specific type of lung cancer. It may help if your cancer has not responded to other treatments or if you have PD-L1-positive lung cancer that hasn't been treated yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a solid tumor that has not responded to standard treatments, or you have advanced non-small cell lung cancer (NSCLC) that is PD-L1 positive (TPS≥50%) and has not been treated before, without EGFR or ALK mutations.
- You have at least one tumor that can be measured on a scan.
- Your organs (blood, liver, kidneys) are working well enough, as shown by blood tests.
- You have not had immunotherapy before (for the lung cancer part of the trial).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, IAP0971, in patients with advanced solid tumors or a specific type of lung cancer (non-small cell lung cancer, or NSCLC) that has high PD-L1 levels. It aims to see if the drug can help when standard treatments have stopped working or are not an option.
This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.
This trial tests a new drug (ES102) combined with an immunotherapy (Toripalimab) for people with advanced non-small cell lung cancer that has stopped responding to standard treatments. It may help those whose tumors have high PD-L1 levels.
This trial tests an experimental drug called IBB0979 for people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to find the right dose and see if the drug can shrink tumors.
This trial tests an experimental drug for people with advanced solid tumors or lymphoma that has not responded to standard treatments and has a specific genetic change (loss of MTAP or CDKN2A genes). The drug is taken by mouth and may work by targeting cancer cells with this change.
This trial tests a new drug called IPG1094 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
Hear when a new Advanced Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.